UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007714 |
|---|---|
| Receipt number | R000009093 |
| Scientific Title | The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose |
| Date of disclosure of the study information | 2012/05/01 |
| Last modified on | 2014/01/08 10:55:18 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose
Acronym
Combination therapy of DPP-4 inhibitor and alfa-glucosidase inhibitor
Scientific Title
The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose
Scientific Title:Acronym
Combination therapy of DPP-4 inhibitor and alfa-glucosidase inhibitor
Region
| Japan |
Condition
Condition
type 2 diabetes mellitus
Classification by specialty
| Medicine in general | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effect of the combination therapy of DPP-4 inhibitor and alfa-glucosidase inhibitors, Acarbose and Voglibose, on the markers of oxidative stress or inflammation
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
Oxitative stress markaer (urinary 8-OHdG, oxidative LDL)
Inflammatory marker (TNF-alfa, hs-CRP)
Key secondary outcomes
Postchallenge plasma glucose concentration
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
NO
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
No need to know
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Administration of Acarbose
Interventions/Control_2
Administration of Voglibose
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. The patients with type 2 diabetes mellitus who gave written informed consent to take part in this clinical study
2. The patients who has been taking DPP-4 inhibitor for more than 3 months and whose HbA1c (JDS) level is 6.5 % or higher.
Key exclusion criteria
1. type 1 diabetes mellitus
2. diabetes ketoacidosis, coma, or pre-coma
3. patients with severe infection, severe trauma, or in perioperative period
4. patients who have allergy to the medicine used in this trial
5.(possible) pregnant women
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masami Tanaka |
Organization
School of Medicine, Keio University
Division name
Department of Internal Medicine
Zip code
Address
35 Shinanomachi, Shinjyuku-ku, Tokyo
TEL
03-5363-3797
tana176k@a7.keio.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masami Tanaka |
Organization
School of Medicine, Keio University
Division name
Department of Internal Medicine
Zip code
Address
35 Shinanomachi, Shinjyuku-ku, Tokyo
TEL
03-5363-3797
Homepage URL
tana176k@a7.keio.jp
Sponsor or person
Institute
Department of Internal Medicine, School of Medicine, Keio University
Institute
Department
Personal name
Funding Source
Organization
Bayer Yakuhin, Ltd.
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 04 | Month | 05 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 04 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 04 | Month | 10 | Day |
Last modified on
| 2014 | Year | 01 | Month | 08 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009093
